GlassScriptPhysician profile
Dave S Khurana
NPI 1700945250
$10,671.67
in general payments reported to CMS, 2019-2025
19 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $2,068 · 2021: $327 · 2022: $730 · 2023: $5,733 · 2024: $783 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,500 · Food and Beverage: $1,938 · Travel and Lodging: $1,460 · Education: $9.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,500.00 |
| Food and Beverage | $1,937.60 |
| Travel and Lodging | $1,459.94 |
| Education | $9.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $5,925.25 | 2020-2023 | |
| Horizon Therapeutics Plc | $2,091.75 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $848.12 | 2019-2024 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $374.34 | 2021-2024 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $191.89 | 2019-2025 | Jynarque |
| Teleflex LLC | $179.33 | 2023-2024 | Deknatel, Titan Sgs |
| Vifor Pharma, INC. | $174.51 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $157.73 | 2024-2025 | |
| Abbott Laboratories | $115.05 | 2022 | |
| Ani Pharmaceuticals, INC. | $110.05 | 2024-2025 | Purified Cortrophin Gel |
| Recor Medical INC | $87.52 | 2025 | Paradise Ultrasound Renal Denervation System |
| Fresenius USA Marketing, INC. | $74.26 | 2021-2025 | Velphoro |
| Mallinckrodt Enterprises LLC | $68.43 | 2019 | |
| Mallinckrodt Hospital Products INC. | $66.25 | 2020-2024 | Acthar |
| Calliditas Therapeutics US INC. | $59.99 | 2022-2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $58.13 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $31.70 | 2019-2024 | |
| Bard Peripheral Vascular, INC. | $30.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.81 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dave Khurana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.